NCT01253603 - Efficacy, Safety, and Pharmacokinetics of QAW039 | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Persistent Asthma

Interventions

DRUG

QAW039 capsules once daily for 28 days

DRUG

Placebo to QAW039 capsules once daily for 28 days

DRUG

Fluticasone propionate inhaler twice daily for 28 days

Trial Locations (26)

19013

Novatis Investigative Site, Upland

27607

Novartis Investigative Site, Raleigh

30281

Novartis Investigative Site, Stockbridge

68123

Novartis Investigative Site, Bellevue

75231

Novartis Investigative Site, Dallas

90025

Novartis Investigative Site, Los Angeles

90048

Novartis Investigative Site, Los Angeles

92024

Novartis Investigative Site, Encinitas

92120

Novartis Investigative Site, San Diego

92123

Novartis Investigative Site, San Diego

92647

Novartis Investigative Site, Huntington Beach

92691

Novartis Investigative Site, Mission Viejo

95117

Novartis Investigative Site, San Jose

95207

Novartis Investigative Site, Stockton

97504

Novartis Investigative Site, Medford

02747

Novartis Investigative Site, North Dartmouth

08009

Novartis Investigative Site, Berlin

08558

Novartis Investigative Site, Skillman

Unknown

Novartis Investigative Site, Jambes

Novartis Investigative Site, Berlin

Novartis Investigative Site, Cologne

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Bucharest

Novartis Investigative Site, Seoul